According to the net profit of the same period last year. 93 the net profit of the drug companies announced, 5 profit over 800 million

Medical Network October 8 as of September 27 close, has 93 pharmaceutical companies issued a 3-quarter notice, the forecast loss of 5 companies, profit Enterprises 88, The loss of about 5.38%, far lower than the pharmaceutical industry 16.36%.

According to the data of the Chinese Institute of Commerce and Industry in early September: by the end of July 2018, China Medicine Industry scale above Enterprise The number reached 7,497, of which the loss of the number of enterprises 1221, the loss of 16.3%, more than last month increased 0.1%, 2018 years ago 7 months, The total loss of pharmaceutical industry 8.55 billion yuan, the cumulative increase of 45.4%.

Note: The data comes from the Sino-commerce Industry Research Institute for REFERENCE. Pharmaceutical industry Operation data show that 2018 1-July, the main business income of China's pharmaceutical industry amounted to 1,440,440,000,000 yuan, the cumulative increase of 14%, up 0.5% from January-June, the industry realized the total profit amounted to 178.93 billion yuan, the cumulative increase of 11.2%,

Fell by 3.2% from January-June.

Note: The data comes from the Sino-commerce Industry Research Institute for REFERENCE.

From the loss of the proportion of enterprises, the loss is about one-third of the overall situation of China's pharmaceutical industry.

But from the industry perspective, pharmaceutical Business No loss-making enterprises, chemical pharmacy, biopharmaceutical, Medical Health And the loss of Chinese patent medicine enterprises have 1-2, the loss of the surface of 3.03%, 10%, 11.12% and 2.63%. But also to see, in the profit of the enterprise, in addition to the health care sub-sector pre-reduction, slightly reduced the proportion of enterprises is also higher, it can be seen that the pharmaceutical industry in the winter is far from the past, business performance continued to increase Pressure. Two-vote system, Strict control of the proportion of drugs, key monitoring and the implementation of the policy of auxiliary drugs to the pharmaceutical industry, the impact of profit is still continuing.

Chemical pharmacy, biopharmaceutical, Pharmaceutical business and Chinese patent medicines pre-cut, slightly minus the total accounted for the breakdown of the industry, respectively, 18.18%, 10%, 16.67% and 13.16%.

Note: data from East net, subdivision of industry classification according to Tongda letter, data for Reference.

Among them, the letter Li tai, le pu medical, Cologne pharmaceutical industry three drug companies in the first three quarters of the net earn over 1 billion, the Cologne pharmaceutical industry growth of over 1.6 times times, le PU medical growth of about 50%. Rui Kang Pharmaceutical and Cabernet Franc three net profit at about 900 million yuan, of which Rui Kang medicine through continuous mergers and acquisitions to expand business performance, has grown into a national pharmaceutical business company, net profit also maintained a relatively stable growth.

Although the year-on-year decline nearly 80%, but mainly because of its 2017-year sale of a free land assets, a one-time income of more than 4 billion yuan, so even in the case of a sharp decline in the same period, still can make a big profit of about 900 million Yuan.

Note: data from East net, subdivision of industry classification according to Tongda letter, data for Reference. Profit of the 88 enterprises, hepalink, le heart health care, Crown Fuk shares, Cologne pharmaceutical industry and pharmaceutical companies, such as purple medicine, the net profit increased by more than 1 time times yoy.

Among them, Hepalink and Le heart health care increased by about 7 times times, mainly due to the two companies in the same period of 2017, the net profit base is relatively low or loss.

Note: data from East net, subdivision of industry classification according to Tongda letter, data for Reference.

In 2015-2015, when the stock market good, the enterprise by the FRY every year to make billions of, even after the stock disaster in 2017, Shanghai Wallace still rely on the net profit of hundreds of millions of Yuan. Think that year, Shanghai Wallace is how the scenery unlimited, Enterprise medicine Business Income is only about 2 billion yuan, unexpectedly can achieve 10 hundreds of millions of yuan net profit, net interest rate level is the industry most, once net profit more than 60%, at the same time also created this family once long-term market value of biological products Enterprise.

As a result, Shanghai Wallace has been occupying the highest net interest rate for several years. unfortunately, Heroes twilight, The hero is no longer brave. The stock market has been plummeting since 2018, and the shares of Shanghai Levin have been losing money, and the range is Widening.

In the first quarter of 2018, the Shanghai Wallace lost nearly 700 million, and the losses in the semi-annual report expanded to 850 million Yuan.

Since July, China's stock market has not improved, before the Mid-Autumn Festival began, although some warmer, but still a drop in the bucket, the three quarterly earnings estimated losses over 1 billion Yuan.

however, It is necessary to note that Shanghai Wallace at the time of the three quarterly results were announced in late August, then the market was near 2,700, and now the market has rebounded to 2,800 points near, Shanghai Lai's stock or market value has rebounded, loss or narrowing.

In addition, Qian Shan Medicine machine in 2017 years loss of nearly 200 million on the basis of a large loss, mainly because the enterprise deep debt crisis, illegal capital occupation, was filed investigation and other mud, according to the industry is expected to risk delisting.

Note: data from East net, subdivision of industry classification according to Tongda letter, data for Reference.

According to the net profit of the same period last year. 93 the net profit of the drug companies announced, 5 profit over 800 million